ClinicalTrials.gg
CompletedNCT03767855Updated Jan 24, 2025

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

A Phase 1 interventional study of CK-3773274 - Granules in Capsule and Placebo - Granules in Capsule in Symptomatic Obstructive Hypertrophic Cardiomyopathy and Healthy Subjects, sponsored by Cytokinetics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Cytokinetics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Enrollment
5th of 11
114 · median 96
Started
2018
the only one that year
Phase 1
2 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
7 of 11
Cytokinetics

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1, and was the 1st registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purposes of this study are to:

  1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects.
  2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses.
  3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses.
  4. Determine the effect of doses of CK-3773274 on the pumping function of the heart.
  5. Evaluate the effect of cytochrome genetic variants on how the body metabolizes CK-3773274.
  6. Evaluate the effect of a meal on how much CK-3773274 is in the blood in healthy adult subjects.
  7. Evaluate whether the amount of CK-3773274 in the blood is the similar for both the tablet and granules in capsule forms of the drug.
03

Conditions studied

  • Symptomatic Obstructive Hypertrophic Cardiomyopathy
  • Healthy Subjects

Keywords

  • CK-3773274
  • CK-274
  • obstructive hypertrophic cardiomyopathy
  • oHCM
  • aficamten
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females (of non-) between 18 and 55 years of age, inclusive
  2. Body weight > 55.0 kg and within 18.0 to 32.0 kg/m2, inclusive
  3. Normal cardiac structure and function, or if abnormalities are present, they are deemed not
  4. Normal to high .
  5. Normal (ECG) or, if abnormalities are present, they are deemed not clinically significant
  6. Clinical laboratory findings within normal range
  7. Negative hepatitis panel (including surface antigen and antibody), and negative antibody screens
  8. Willing and able to refrain from strenuous exercise (eg, activity which could be expected to cause muscle soreness)
  9. For Arms 5 and 6 only: Subject is a CYP2D6 poor metabolizer

Exclusion criteria

Exclusion Criteria:

  1. History of any significant illness or disorder
  2. History of stomach or intestinal surgery or resection (appendectomy, hernia repair, and/or cholecystectomy will be allowed)
  3. A illness within 4 weeks of Check-in
  4. Inability to swallow capsules or tablets
  5. History of or current substance abuse (drug or alcohol), known drug or alcohol dependence within the last 2 years prior to Screening, or positive test for drugs of abuse during the screening period
  6. Use of any tobacco-containing or nicotine-containing products within 3 months prior to Check-in
  7. Participation in any other study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in
  8. Any blood donation within 60 days of dosing, plasma donation within 30 days of dosing, or receipt of blood products within 2 months prior to Check-in
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    CK-3773274 for SAD Cohorts

    Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274

    Drug: CK-3773274 - Granules in Capsule

  • Placebo comparator
    Placebo for SAD Cohorts

    Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo

    Drug: Placebo - Granules in Capsule

  • Experimental
    CK-3773274 for MAD Cohorts

    Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274

    Drug: CK-3773274 - Granules in Capsule

  • Placebo comparator
    Placebo for MAD Cohorts

    Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo

    Drug: Placebo - Granules in Capsule

  • Experimental
    CK-3773274 for CYP2D6 Cohort

    Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274

    Drug: CK-3773274 - Granules in Capsule

  • Placebo comparator
    Placebo for CYP2D6 Cohort

    Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo

    Drug: Placebo - Granules in Capsule

  • Experimental
    Food Effect

    Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion

    Drug: CK-3773274 - Granules in Capsule

  • Experimental
    Relative Bioavailability

    Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.

    Drug: CK-3773274 - Granules in Capsule · Drug: CK-3773274 - Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects.

    Subject incidence of AEs, SAEs, and reduced LVEF

    Time frame: SAD Cohorts: Day -1 - Day 10; CYP2D6 Cohort: Day -1 - Day - 24; MAD Cohorts: Day -1 - Day 27; Food Effect Cohort: Day -1 - Day 24; relative Bioavailability Cohort: Day -1 - Day 29

Secondary outcomes

  1. Cmax of CK-3773274 after single and multiple ascending doses

    Maximum concentration after dosing (Cmax) following single and multiple doses of CK-3773274 administered to healthy subjects

    Time frame: SAD Cohorts: Day 1; CYP2D6 Cohort: Day 1; MAD Cohorts: Day 14 or Day 17; Food Effect Cohort: Day 15; Relative Bioavailability Cohort: Day 15

  2. Change in absolute reduction in ejection fraction relative to baseline with doses of CK-3773274

    Changes from baseline in LVEF as measured by echocardiography with doses of CK-3773274

    Time frame: Time Frame for SAD Cohorts: Day -1 - Day 10; Time Frame for CYP2D6 Cohort: Day -1 - Day 24; Time Frame for MAD Cohorts: Day -1 - Day 27

  3. Assess the effect of CYP2D6 genetic variants on the PK of CK-3773274

    Maximum concentration after dosing (Cmax) following a single dose administered to CYP2D6 poor metabolizers

    Time frame: Day -1 - Day 24

  4. Assess the effect of a meal on how much CK-3773274 is in the blood in healthy subjects

    Maximum concentration after dosing (Cmax) following single and multiple doses of CK-3773274 administered to healthy subjects in fed and fasted states

    Time frame: Day -1 - Day 24

  5. Relative bioavailability of CK-3773274 formulated as granules in capsule versus a tablet in healthy adult subjects

    PK parameters such as AUC calculated using plasma concentrations of CK-3773274

    Time frame: Time Frame for Bioavailability Cohort: Day -1 - Day 29

07

Study locations

1 site
  • Clinical Site
    Tempe, Arizona 85283, United States
08

References and documents

Publications

  • Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD. A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants. JACC Basic Transl Sci. 2022 Aug 10;7(8):763-775. doi: 10.1016/j.jacbts.2022.04.008. eCollection 2022 Aug. PubMed 36061336 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2020, 12 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2018
First posted
Dec 7, 2018
StartActual
Dec 4, 2018
Primary completionActual
Jan 3, 2020
CompletionActual
Jan 3, 2020
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03767855
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Dec 4, 2018
Primary completion
Jan 3, 2020
Completion
Jan 3, 2020
Last update
Jan 24, 2025

Study contacts

Study Director MD
study director · Cytokinetics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion